Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis

Table 3

Analyses of adverse events (grade 3).

Adverse events	References	Relative risk; (95% confidence interval)		Heterogeneity
Sipuleucel-T
Fatigue	Small et al., 2006; Higano et al., 2009; Kantoff et al., 2010	0.89 (0.27–3.01)	0.86	, = 0%
Headache		2.03 (0.23–17.9)	0.52	, = 0%
Back pain		0.88 (0.4–1.91)	0.74	, = 0%
Arthralgia		0.93 (0.35–2.48)	0.88	, = 0%
Constipation		0.23 (0.03–1.48)	0.12	, = 0%
Diarrhea		0.17 (0.02–1.58)	0.12	—
Androgen receptor-directed therapies
Fatigue	Fizazi et al., 2012; Scher et al., 2012; Beer and Tombal, 2014; Rathkopf et al., 2014	0.92 (0.49–1.93)	0.5	, = 0%
Headache		1.7 (0.44–6.58)	0.45	, = 49%
Back pain		0.75 (0.54–1.03)	0.07	, = 0%
Arthralgia		1.21 (0.76–1.92)	0.43	, = 0%
Constipation		1.26 (0.51–3.14)	0.62	, = 0%
Diarrhea		1.26 (0.56–2.83)	0.57	, = 16%